4 years ago

PhoreMost Raises £33M in Series B Funding for Novel Drug Development

  • PhoreMost, a UK-based AI drug startup, has raised £33m in a Series B funding round led by BGF and new investors XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures

  • The funding will support the development of its lead asset and innovative pipeline.

      • ProblemHealthcare

      "Many diseases are considered 'undruggable' because their targets are difficult to reach with traditional drug development methods. This means that patients with these diseases often have limited or no treatment options."

      Solution

      "PhoreMost's SITESEEKER platform uses AI to identify new therapeutic targets for diseases and quickly develop novel drugs for these targets. This allows them to develop treatments for diseases that were previously considered undruggable."

      Covered on